In which country is baricitinib manufactured?

Baricitinib, also known as baricitinib, is an oral JAK inhibitor jointly developed by the famous American pharmaceutical company Eli Lilly and the American Incyte Company. The drug mainly reduces the release of inflammatory cytokines by selectively inhibiting the JAK1 and JAK2 signaling pathways. It is widely used to treat moderate to severe rheumatoid arthritis and atopic dermatitis, and was approved for adjuvant treatment of some severe COVID-19 patients during the new coronavirus epidemic. As an innovative targeted drug, baricitinib is produced and sold globally by Eli Lilly.

Currently, the original version of baricitinib is mainly manufactured at Eli Lilly pharmaceutical plants in the United States and Europe. Eli Lilly has modern production bases in Indiana, Ireland, Spain and other places that comply with GMP standards. The synthesis of pharmaceutical raw materials, preparation processing and quality control are all carried out under strict supervision. In addition, before drugs enter different countries, they must be approved by national drug regulatory agencies (such as FDA, EMA, NMPA) to ensure their quality, safety and effectiveness.

In the Chinese market, baricitinib has been approved for marketing by the National Food and Drug Administration (NMPA) and has been included in the national medical insurance directory, which has greatly improved the accessibility and medication protection of domestic patients. However, there is currently no domestically produced generic version on the market in China. The baricitinib used by patients is mostly an imported drug originally developed by Eli Lilly and introduced by domestic agencies or drug distribution platforms. The main sales channels are major hospital pharmacies or medical insurance designated pharmacies.

As the market demand for JAK inhibitor drugs continues to grow, some domestic companies have deployed the research and development of related generic drugs. However, as of2025, the legally supplied baricitinib on the market is still dominated by the original drug manufactured by Eli Lilly and Company of the United States. Therefore, patients should obtain drugs through formal channels when choosing medications to avoid quality and efficacy risks caused by informal generic drugs and ensure the safety and effectiveness of treatment.

Reference materials:https://www.drugs.com/